- Trials with a EudraCT protocol (162)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
162 result(s) found for: Muscle fatigue.
Displaying page 1 of 9.
EudraCT Number: 2012-002969-35 | Sponsor Protocol Number: P40919/SAFFE2012 | Start Date*: 2013-08-19 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: Slow-wave sleep and daytime functioning in chronic fatigue syndrome: effects of sodium oxybate | |||||||||||||
Medical condition: Chronic fatigue syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005534-19 | Sponsor Protocol Number: FRIA_FATSURG_1 | Start Date*: 2012-01-31 |
Sponsor Name:Vrije Universiteit Brussel | ||
Full Title: The effect of peri-operative anti-inflammatory treatment on postoperative muscle weakness and muscle fatigue in elderly elective surgery patients: a double blinded randomized placebo-controlled trial. | ||
Medical condition: Post-operative muscle weakness, fatigue and inflammation. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002370-12 | Sponsor Protocol Number: IMI2016-2 | Start Date*: 2016-12-29 | ||||||||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | ||||||||||||||||||
Full Title: PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME | ||||||||||||||||||
Medical condition: Immunoglobulin deficiency and recurrent infections with chronic fatigue syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003359-33 | Sponsor Protocol Number: MABS06 | Start Date*: 2023-06-21 | |||||||||||
Sponsor Name:MUMC | |||||||||||||
Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers | |||||||||||||
Medical condition: Mitochondrial myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001844-36 | Sponsor Protocol Number: 1 | Start Date*: 2017-09-13 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: MethylphenIdate for fatigue in haematological cancer. A randomized, double-blind, placebo-controlled, CROssover trial - the MICRO trial | |||||||||||||
Medical condition: Cancer related fatigue in patients with haematological cancer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001250-41 | Sponsor Protocol Number: KOLD | Start Date*: 2015-04-15 |
Sponsor Name:Region Östergötland | ||
Full Title: THE IMPACT OF VITAMIN D ON PHYSICAL TRAINING OF VITAMIN D DEFICIENT PATIENTS WITH COPD: A PROSPECTIVE RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTI-CENTRE STUDY | ||
Medical condition: Patients with chronic obstructive pulmonary disease (COPD) and concomitant vitamin D deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000144-25 | Sponsor Protocol Number: 234820 | Start Date*: 2019-03-08 | ||||||||||||||||
Sponsor Name:King's College Hospital NHS Foundation Trust | ||||||||||||||||||
Full Title: Multicentre prospective double blinded randomised controlled trial of the effect of intravenous iron supplementation and exercise training in Iron deficient, but not anaemic, patients with Chronic ... | ||||||||||||||||||
Medical condition: Iron deficiency in stage 3-4 CKD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000145-12 | Sponsor Protocol Number: 5997 | Start Date*: 2012-08-15 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Rituximab for the Treatment of Fatigue in Primary Biliary Cirrhosis (PBC) | |||||||||||||
Medical condition: Severe fatigue in Primary Biliary Cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003644-12 | Sponsor Protocol Number: 2014-003644-12 | Start Date*: 2015-02-20 | |||||||||||||||||||||
Sponsor Name:Neuromuscular Research Unit, Rigshospitalet | |||||||||||||||||||||||
Full Title: The effect of Triheptanoin in adults with McArdle Disease (Glycogen Storage Disease Type V) | |||||||||||||||||||||||
Medical condition: McArdle Disease Also called: Glycogen Storage Disease Type V or Myophosphorylase Deficiency | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002610-14 | Sponsor Protocol Number: 79835 | Start Date*: 2021-09-08 | |||||||||||
Sponsor Name:Aarhus University Hospital, Department of Neurology | |||||||||||||
Full Title: Mestinon and Salbutamol Tolerability and Efficacy as therapy for Post-COVID-19 Myopathy - A randomized, placebo-controlled, rater and subject-blinded, 2x2 crossover study. | |||||||||||||
Medical condition: Post-COVID-19 Myopathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001375-11 | Sponsor Protocol Number: not applicable | Start Date*: 2007-05-16 |
Sponsor Name: | ||
Full Title: Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease Long-term follow-up of patients receiving commercially available Myozyme | ||
Medical condition: Pompe disease (glycogen storage disease type II) is a genetic, lysosomal storage disorder with a frequency of 1 in 40.000 newborns. The disease is caused by deficiency of alpha-glucosidase, a lysos... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002721-29 | Sponsor Protocol Number: 08486 | Start Date*: 2018-12-24 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy | ||
Medical condition: Mitochondrial Myopathy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2018-000755-40 | Sponsor Protocol Number: ATB200-03 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Algluc... | |||||||||||||
Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) SE (Completed) HU (Completed) BE (Completed) SK (Completed) ES (Completed) NL (Completed) BG (Prematurely Ended) SI (Completed) GR (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003461-17 | Sponsor Protocol Number: 71272 | Start Date*: 2020-01-07 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF) | ||
Medical condition: Heart failure with preserved ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000985-36 | Sponsor Protocol Number: EMCAM-2011-001 | Start Date*: 2013-02-22 | |||||||||||
Sponsor Name:JOSE MANUEL GARCIA DOMINGUEZ | |||||||||||||
Full Title: Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as "responders" and "not responders" under t... | |||||||||||||
Medical condition: Spasticity due to multiple sclerosis identified as "responders" and "not responders" under treatment with Sativex | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005494-11 | Sponsor Protocol Number: VERI-LONG | Start Date*: 2023-03-14 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to p... | |||||||||||||
Medical condition: Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001277-23 | Sponsor Protocol Number: ARGX-113-2007 | Start Date*: 2022-10-26 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Phar... | |||||||||||||
Medical condition: Active Idiopathic Inflammatory Myopathy (IIM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) LT (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) ES (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003868-42 | Sponsor Protocol Number: R123899 | Start Date*: 2020-05-19 | |||||||||||
Sponsor Name:University of Manchester | |||||||||||||
Full Title: A randomised, phase IIa treatment delayed-start trial of the oral JAK 1/2 inhibitor, baricitinib, in the treatment of adult idiopathic inflammatory myopathy | |||||||||||||
Medical condition: Idiopathic Inflammatory Myopathy (IIM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004166-37 | Sponsor Protocol Number: 100424 | Start Date*: 2023-05-02 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric oxygenation for patients with orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID. Prospectively randomized cross- over study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-000954-67 | Sponsor Protocol Number: ATB200-07 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease | |||||||||||||
Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) DK (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) SI (Trial now transitioned) AT (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
